Company overview
Basic information
Company name
Mano karkasas, MB
Company code
306332838
VAT code
LT100016018316
Registered address
Jonavos r. sav., Kulvos sen., Kurmagalos k., Kauno kel. 53A, LT-55245
Registration date
2023-06-06
Company age: 3 y. 4 mo.
Contact information
Edit data
Phone
Presented as an image – cannot be copied
Email
Presented as an image – cannot be copied
Website
None
Company manager
For registered members only
Log in
Indicators
Risk factors
Activity
Legal form
Small partnership
NACE activity
New construction
Ownership form
Private without foreign capital
MB Mano karkasas
Company code: 306332838
Address: Jonavos r. sav., Kulvos sen., Kurmagalos k., Kauno kel. 53A, LT-55245
VAT code: LT100016018316
Description
This description was generated by artificial intelligence.
Mano karkasas, MB (company code 306332838) is a private small partnership registered in 2023 and currently operational. It operates in the national private non-financial companies sector and is structured as a privately owned entity, with Lithuanian natural and legal persons holding more than 50% of the authorised capital and no foreign investor capital. Governance is described as CEO only. The company is classified as micro-sized and is engaged in EVRK activity F.41.00.10, New construction. Its registered address is in Kurmagalos k., Kulvos sen., Jonavos r. sav., Kauno apskritis. Financially, the company generated revenue of €161.4K in 2025, slightly below 2024, while still remaining above the 2023 level. Net profit reached €6.3K in 2025, compared with €5.9K in 2024, and the net profit margin improved to 3.9%. Over the two-year period from 2023 to 2025, revenue increased by 46.8%. Equity stood at €14.0K at the end of 2025, with liabilities of €3.9K and total assets of €17.9K. The company had an average of 1 employee in 2025 and so far in 2026.
Download a detailed company report
Make confident decisions with all the information about Mano karkasas, MB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.